SavedAdd your journal

Journals / MN Kardiyoloji / 2020 / Cilt: 27 - Sayı: 3

Cardiovascular Effects of Chronic Domperidon Use: Up to Date Information

Kronik Domperidon Kullanımının Kardiyovasküler Sistem Üzerine Etkisi: Güncel Bilgiler

Kerim ESENBOĞA
Emir BASKOVSKI
Nil ÖZYÜNCÜ
Türkan Seda TAN
Eralp TUTAR
Pages
180–182
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article we review current data regarding cardiovascular effects of chronic domperidon use.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Domperidone is widely used for pharmacological treatment of gastroparesis, gastroesophageal reflux diesase and functional dyspepsia.
📊
Key Findings & Data:Similarly, risk of sudden cardiac death and ventricular arrythmias has been reported to be increased, although mainly by meta-analysis of retrospective data.
💡
Conclusion & Impact:In this article we review current data regarding cardiovascular effects of chronic domperidon use.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Domperidone is widely used for pharmacological treatment of gastroparesis, gastroesophageal reflux diesase and functional dyspepsia. In in-vitro studies it has been observed that domperidon prolongs repolarizaton and action potential duratiın by binding to cardiar hERG (human ether-a-go-go-related gene) protein, which is a subunit of late rapid repolarizing potassium channel (Ikr). Various case reports and retrospective studies have reported prolongation of QT interval with chronic domperidon use. Similarly, risk of sudden cardiac death and ventricular arrythmias has been reported to be increased, although mainly by meta-analysis of retrospective data. In this article we review current data regarding cardiovascular effects of chronic domperidon use.

Özet

Domperidon gastroparezi, gastroözefageal reflü ve fonksiyonel dispepsi gibi birçok intestinal motilite bozukluklarının farmakolojik tedavisinde kullanılmaktadır. in vitro çalışmalarda domperidonun geç hızlı repolarizasyonu sağlayan potasyum kanallarının (IKr) subünitesi olan kardiyak hERG (human ether-a-go-go-related gene) proteinlerine bağlanarak repolarizasyonu geciktirdiği ve aksiyon potansiyeli süresini uzattığı gösterilmiştir. Birçok vaka sunumu ve retrospektif çalışmada kronik domperidon kullanımı ile QT intervalinde uzama saptanmıştır. Benzer şekilde çoğunlukla retrospektif verilerin meta-analizlerinde domperidon kullanımı ani kardiyak ölüm ve ventriküler aritmi riskinde artışa neden olabileceği gösterilmiştir. Bu yazıda kronik domperidon kullanımın kardiyovasküler sistem üzerine etkilerinin güncel derlemesi sunulmuştur.

🔖

Cite This Article

ESENBOĞA, K., BASKOVSKI, E., ÖZYÜNCÜ, N., TAN, T. S., TUTAR, E. (2020). Cardiovascular Effects of Chronic Domperidon Use: Up to Date Information. MN Kardiyoloji, Cilt: 27 - Sayı: 3, 180–182. https://ajindex.com/articles/297334

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Jacoby HI. Brodie DA. Gastrointestinal actions of metoclopramide. An experimental study. Gastroenterology. 1967;52(4):676-84
  2. Reddymasu SC. Soykan I. McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102(9):2036-45
  3. Tonini M. Cipollina L. Poluzzi E. Crema F. Corazza GR. De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004; 19(4):379-90
  4. Barone JA. Domperidone: a peripherally acting dopa mi - ne2-receptor antagonist. Ann Pharmacother. 1999;33(4): 429-40
  5. Doggrell SA. Hancox JC. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf. 2014;13(1):131-8
  6. Osadchy A. Moretti ME. Koren G. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials. Obstet Gynecol Int. 2012;2012:642893
  7. Ingram J. Taylor H. Churchill C. et al. Metoclopramide or domperidone for increasing maternal breast milk output: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2012;97(4):241-5
  8. Rao AS. Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1): 11-9
  9. Claassen S. Zunkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharma - co logy. 2005;74(1):31-6
  10. Heykants J. Hendriks R. Meuldermans W. et al. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administrationn Eur J Drug Metab Pharmacokinet. 1981;6(1):61-70
  11. Simard C. Michaud V. Gibbs B. Massé R. Lessard E. Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004;34 (11-12):1013-23
  12. Couture L. Nash JA. Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev. 2006;58(2): 244-58
  13. Stork D. Timin EN. Berjukow S. et al. State dependent dissociation of HERG channel inhibitors. Br J Pharmacol. 2007;151(8):1368-76
  14. Rocha CM. Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720-3
  15. Boyce MJ. Baisley KJ. Warrington SJ. Pharmacoki